104 related articles for article (PubMed ID: 23079531)
1. A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer.
Fry SA; Sinclair J; Timms JF; Leathem AJ; Dwek MV
Cancer Lett; 2013 Jan; 328(2):335-44. PubMed ID: 23079531
[TBL] [Abstract][Full Text] [Related]
2. The lectin Helix pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human breast cancer.
Rambaruth ND; Greenwell P; Dwek MV
Glycobiology; 2012 Jun; 22(6):839-48. PubMed ID: 22322011
[TBL] [Abstract][Full Text] [Related]
3. Cadherin-5: a biomarker for metastatic breast cancer with optimum efficacy in oestrogen receptor-positive breast cancers with vascular invasion.
Fry SA; Robertson CE; Swann R; Dwek MV
Br J Cancer; 2016 Apr; 114(9):1019-26. PubMed ID: 27010749
[TBL] [Abstract][Full Text] [Related]
4. Expression of Helix pomatia lectin binding glycoproteins in women with breast cancer in relationship to their blood group phenotypes.
Welinder C; Jansson B; Ferno M; Olson H; Baldetorp B
J Proteome Res; 2009 Feb; 8(2):782-7. PubMed ID: 18998722
[TBL] [Abstract][Full Text] [Related]
5. Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues.
Turtoi A; Dumont B; Greffe Y; Blomme A; Mazzucchelli G; Delvenne P; Mutijima EN; Lifrange E; De Pauw E; Castronovo V
J Proteome Res; 2011 Jul; 10(7):3160-82. PubMed ID: 21534635
[TBL] [Abstract][Full Text] [Related]
6. Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.
Böhm D; Keller K; Wehrwein N; Lebrecht A; Schmidt M; Kölbl H; Grus FH
Oncol Rep; 2011 Nov; 26(5):1051-6. PubMed ID: 21837365
[TBL] [Abstract][Full Text] [Related]
7. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
8. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
9. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.
Abd Hamid UM; Royle L; Saldova R; Radcliffe CM; Harvey DJ; Storr SJ; Pardo M; Antrobus R; Chapman CJ; Zitzmann N; Robertson JF; Dwek RA; Rudd PM
Glycobiology; 2008 Dec; 18(12):1105-18. PubMed ID: 18818422
[TBL] [Abstract][Full Text] [Related]
10. Serum protein levels following surgery in breast cancer patients: a protein microarray approach.
Perez-Rivas LG; Jerez JM; Fernandez-De Sousa CE; de Luque V; Quero C; Pajares B; Franco L; Sanchez-Muñoz A; Ribelles N; Alba E
Int J Oncol; 2012 Dec; 41(6):2200-6. PubMed ID: 23076779
[TBL] [Abstract][Full Text] [Related]
11. Identification of O-Linked Glycoproteins Binding to the Lectin Helix pomatia Agglutinin as Markers of Metastatic Colorectal Cancer.
Peiris D; Ossondo M; Fry S; Loizidou M; Smith-Ravin J; Dwek MV
PLoS One; 2015; 10(10):e0138345. PubMed ID: 26495974
[TBL] [Abstract][Full Text] [Related]
12. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms.
Bones J; Byrne JC; O'Donoghue N; McManus C; Scaife C; Boissin H; Nastase A; Rudd PM
J Proteome Res; 2011 Mar; 10(3):1246-65. PubMed ID: 21142185
[TBL] [Abstract][Full Text] [Related]
13. Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer.
Dwek MV; Ross HA; Leathem AJ
Proteomics; 2001 Jun; 1(6):756-62. PubMed ID: 11677781
[TBL] [Abstract][Full Text] [Related]
14. Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma.
Hongsachart P; Huang-Liu R; Sinchaikul S; Pan FM; Phutrakul S; Chuang YM; Yu CJ; Chen ST
Electrophoresis; 2009 Apr; 30(7):1206-20. PubMed ID: 19294700
[TBL] [Abstract][Full Text] [Related]
15. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer.
Ueda K; Katagiri T; Shimada T; Irie S; Sato TA; Nakamura Y; Daigo Y
J Proteome Res; 2007 Sep; 6(9):3475-83. PubMed ID: 17705522
[TBL] [Abstract][Full Text] [Related]
16. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.
Howard EM; Lau SK; Lyles RH; Birdsong GG; Tadros TS; Umbreit JN; Kochhar R
Int J Clin Oncol; 2004 Jun; 9(3):154-60. PubMed ID: 15221598
[TBL] [Abstract][Full Text] [Related]
17. Lectin microarray profiling of metastatic breast cancers.
Fry SA; Afrough B; Lomax-Browne HJ; Timms JF; Velentzis LS; Leathem AJ
Glycobiology; 2011 Aug; 21(8):1060-70. PubMed ID: 21507904
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
19. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of archival breast cancer serum.
Zeidan BA; Cutress RI; Murray N; Coulton GR; Hastie C; Packham G; Townsend PA
Cancer Genomics Proteomics; 2009; 6(3):141-7. PubMed ID: 19487543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
